| | |
 |  | |
 | ||
 | | 
08 May 2012
Notice of Posting of Annual Report 01 May 2012 Appointment of experienced biotechnology CEO as part of succession planning 05 April 2012 Preliminary Unaudited Results for the 12 months ended 31 December 2011     Subscribe to our Email List | |  Verona Pharma plc is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough. Verona Pharma currently has three potential drug treatments under development and continues to look for other possible drug development opportunities aimed at the respiratory and inflammatory diseases markets. Verona Pharma is incorporated in the United Kingdom and has its principal office in central London. Verona Pharma is traded on the AIM stock exchange under the symbol VRP. The information on this website is made available pursuant to AIM Rule 26. This website was last updated on 5 January 2012. | | |
| ||
| | |
| ||
| Home Company Information Products AIM Rule 26 News Releases Contact For Staff | |
| ©2006 Verona Pharma Plc All Rights Reserved. | Disclaimer | |